Hematology Fellowship Programs

This is a research-intensive fellowship focused on an aspect of benign or malignant hematology. The chosen research project could be fundamental, translational or clinical in nature, work towards which will constitute 75% of the fellow’s time. Fellows will be expected to present their work at one or more conferences and prepare a manuscript for publication. Clinical duties will comprise 25% of the fellow’s time (eg ten outpatient half-day clinics per month (possibly alternating weeks with two or three half-day clinics per week), or two half-day clinics per week with one weekend “on-call” per month). Fellows will be expected to present their research topic to hematology trainees at one of their academic half-days. Read full description here.

This is a clinical fellowship focused on the diagnosis and treatment of patients with lymphoproliferative disorders (LPD). Fellows will be expected to participate in a clinical and/or translational research project with the aim to present their work at conferences and prepare a manuscript for publication. They will be exposed to patients referred for evaluation and management of LPD in the frontline or relapse settings and will gain proficiency in delivering conventional therapy, experimental therapy in the context of clinical trials and cell therapy (transplant and chimeric antigen receptor T-cell therapy (CAR-T)). Clinical duties will consist of 3-4 outpatient half-day clinics/week and one weekend “on-call” per month. Fellows will be expected to participate in lymphoma-related teaching sessions with the hematology trainees, attend tumor boards and academic Hematology rounds, with remaining time dedicated to research. Read full description here.

This is a clinical fellowship focused on the diagnosis and treatment of patients with MM. Fellows will be expected to participate in a clinical and/or translational research project with the aim to present their work at conferences and prepare a manuscript for publication. They will be exposed to patients referred for evaluation and management of MM in the frontline or relapse settings and will gain proficiency in delivering conventional therapy, experimental therapy in the context of clinical trials, and cell therapy (transplant and chimeric antigen receptor T-cell therapy (CAR-T)). Clinical duties will consist of 3-4 outpatient half-day clinics/week and one weekend “on-call” per month. Fellows will be expected to participate in MM-related teaching sessions with the hematology trainees, attend tumor boards and academic Hematology rounds, with remaining time dedicated to research. Read full description here.